Search

Your search keyword '"Caux, C"' showing total 15 results
Start Over Author "Caux, C" Journal annals of oncology
15 results on '"Caux, C"'

1. The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade

Author

Foy, J.-P., Bertolus, C., Michallet, M.-C., Deneuve, S., Incitti, R., Bendriss-Vermare, N., Albaret, M.-A., Ortiz-Cuaran, S., Thomas, E., Colombe, A., Py, C., Gadot, N., Michot, J.-P., Fayette, J., Viari, A., Van den Eynde, B., Goudot, P., Devouassoux-Shisheboran, M., Puisieux, A., Caux, C., Zrounba, P., Lantuejoul, S., and Saintigny, P.

Published
2017
Full Text
View/download PDF

3. ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients

Author

Trédan, O, Ménétrier-Caux, C, Ray-Coquard, I, Garin, G, Cropet, C, Verronèse, E, Bachelot, T, Rebattu, P, E Heudel, P, Cassier, P, Chabaud, S, Croughs, T, Dupont, P, C Cadore, A, Clapisson, G, Delgado, A, Bardin-dit-Courageot, C, Rigal, C, N’Kodia, A, Gilles-Afchain, L, Morre, M, Pérol, D, Blay, J Y, and Caux, C

Published
2018
Full Text
View/download PDF

4. ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients

Author

Trédan, O., Ménétrier-Caux, C., Ray-Coquard, I., Garin, G., Cropet, C., Verronèse, E., Bachelot, T., Rebattu, P., Heudel, P. E., Cassier, P., Chabaud, S., Croughs, T., Dupont, P., Cadore, A. C., Clapisson, G., Delgado, A., Bardin-dit-Courageot, C., Rigal, C., NʼKodia, A., Gilles-Afchain, L., Morre, M., Pérol, D., Blay, J. Y., and Caux, C.

Published
2015
Full Text
View/download PDF

5. 819TiP COLIBRI trial (GINECO-CE108b): A multicenter, window study evaluating immune impact and safety of nivolumab in combination with ipilimumab before initial radio-chemotherapy (RTCT) treatment for locally advanced cervix cancer

Author

Ray-Coquard, I.L., primary, Kaminsky-Forrett, M-C., additional, Joly, F., additional, Montané, L., additional, Bello Roufai, D., additional, Savoye, A.M., additional, Angelergues, A., additional, Hardy-Bessard, A-C., additional, Mouret Reynier, M.A., additional, Deluche, E., additional, Caux, C., additional, Saintigny, P., additional, Péré, H., additional, Treilleux, I., additional, Betrian, S., additional, and Lecuru, F., additional

Published
2021
Full Text
View/download PDF

9. A phase I dose escalation trial evaluating the impact of an in situ immunization strategy with intra-tumoral injections of Pexa-Vec in combination with ipilimumab in advanced solid tumors with injectable lesions

Author

Marabelle, A., primary, Eberst, L., additional, Terret, C., additional, Pilleul, F., additional, Mastier, C., additional, Bouhamama, A., additional, Gilles-Afchain, L., additional, Laurent, S., additional, Delzano, I., additional, Reynaud, C., additional, Caux, C., additional, Garin, G., additional, Bidaux, A.-S., additional, Perol, D., additional, Stojkowitz, N., additional, Homerin, M., additional, Leenders, H., additional, and Cassier, P., additional

Published
2018
Full Text
View/download PDF

11. 110TiP - A phase I dose escalation trial evaluating the impact of an in situ immunization strategy with intra-tumoral injections of Pexa-Vec in combination with ipilimumab in advanced solid tumors with injectable lesions

Author

Marabelle, A., Eberst, L., Terret, C., Pilleul, F., Mastier, C., Bouhamama, A., Gilles-Afchain, L., Laurent, S., Delzano, I., Reynaud, C., Caux, C., Garin, G., Bidaux, A.-S., Perol, D., Stojkowitz, N., Homerin, M., Leenders, H., and Cassier, P.

Published
2018
Full Text
View/download PDF

12. Technology & tools development

Author

Pefani, E., primary, Panoskaltsis, N., additional, Mantalaris, A., additional, Georgiadis, M. C., additional, Pistikopoulos, E. N., additional, Aguilar-Mahecha, A., additional, Lafleur, J., additional, Seguin, C., additional, Rosenbloom, M., additional, Przybytkowski, E., additional, Pelmus, M., additional, Diaz, Z., additional, Batist, G., additional, Basik, M., additional, Tavernier, J., additional, Brunet, L., additional, Bazot, J., additional, Chemelle, M., additional, Dalban, C., additional, Guiu, S., additional, di Martino, C., additional, Lehtio, J., additional, Branca, M., additional, Johansson, H., additional, Orre, M., additional, Granholm, V., additional, Forshed, J., additional, Perez-Bercoff, M., additional, Kall, L., additional, Nielsen, K. V., additional, Andresen, L., additional, Muller, S., additional, Matthiesen, S., additional, Schonau, A., additional, Oktriani, R., additional, Wahyono, A., additional, Haryono, S., additional, Utomo, A., additional, Aryandono, T., additional, Gagnon-Kugler, T., additional, Rousseau, C., additional, Alcindor, T., additional, Aloyz, R., additional, Assouline, S., additional, Bachvarov, D., additional, Belanger, L., additional, Camlioglu, E., additional, Cartillone, M., additional, Chabot, B., additional, Christodoulopoulos, R., additional, Courtemanche, C., additional, Constantin, A., additional, Benlimame, N., additional, Dao, I., additional, Dalfen, R., additional, Gosselin, L., additional, Habbab, F., additional, Hains, M., additional, Haliotis, T., additional, Nielsen, T. H., additional, Joncas, M., additional, Kavan, P., additional, Klink, R., additional, Langlaben, A., additional, Lebel, M., additional, Lesperance, B., additional, Mann, K., additional, Masson, J., additional, Metrakos, P., additional, McNamara, S., additional, Miller, W. H., additional, Orain, M., additional, Panasci, L., additional, Paquet, E., additional, Phillie, M., additional, Qureshi, S., additional, Rodrigue, D., additional, Salman, A., additional, Spatz, A., additional, Tetu, B., additional, Tosikyan, A., additional, Tsatoumas, M., additional, Vuong, T., additional, Ruijtenbeek, R., additional, Houtman, R., additional, de Wijn, R., additional, Boender, P., additional, Hilhorst, R., additional, Cohen, Y., additional, Onn, A., additional, Lax, A., additional, Yosepovich, A., additional, Litz, S., additional, Kalish, S., additional, Felemovicius, R., additional, Hout-Silony, G., additional, Gutman, M., additional, Shabtai, M., additional, Rosin, D., additional, Valeanu, A., additional, Winkler, E., additional, Sklair-Levy, M., additional, Kaufman, B., additional, Barshack, I., additional, Canu, V., additional, Sacconi, A., additional, Biagioni, F., additional, Mori, F., additional, di Benedetto, A., additional, Lorenzon, L., additional, di Agostino, S., additional, Cambria, A., additional, Germoni, S., additional, Grasso, G., additional, Blandino, R., additional, Panebianco, V., additional, Ziparo, V., additional, Federici, O., additional, Muti, P., additional, Strano, S., additional, Carboni, F., additional, Mottolese, M., additional, Diodoro, M. G., additional, Pescarmona, E., additional, Garofalo, A., additional, Blandino, G., additional, Ho, T., additional, Feng, L., additional, Lintula, S., additional, Orpana, K. A., additional, Stenman, J., additional, El Messaoudi, S., additional, Mouliere, F., additional, del Rio, M., additional, Guedj, A. S., additional, Gongora, C., additional, Molina, F. M., additional, Lamy, P. J., additional, Lopez-Crapez, E., additional, Rolet, F., additional, Mathonnet, M., additional, Ychou, M., additional, Pezet, D., additional, Thierry, A. R., additional, Manuarii, M., additional, Tredan, O., additional, Bachelot, T., additional, Clapisson, G., additional, Courtier, A., additional, Parmentier, G., additional, Rabeony, T., additional, Grives, A., additional, Perez, S., additional, Mouret, J. F., additional, Perol, D., additional, Chabaud, S., additional, Ray-Coquard, I., additional, Labidi-Galy, I., additional, Heudel, P., additional, Pierga, J. Y., additional, Caux, C., additional, Blay, J. Y., additional, Pasqual, N., additional, and Menetrier-Caux, C., additional

Published
2012
Full Text
View/download PDF

13. P3.13 Immune Status Stratification of Metastatic Breast Cancer Patients: Lympho-Divpenia Predicts Overall Survival

Author

Manuarii, M., primary, Tredan, O., additional, Bachelot, T., additional, Clapisson, G., additional, Courtier, A., additional, Parmentier, G., additional, Rabeony, T., additional, Grives, A., additional, Perez, S., additional, Mouret, J.F., additional, Perol, D., additional, Chabaud, S., additional, Ray-Coquard, I., additional, Labidi-Galy, I., additional, Heudel, P., additional, Pierga, J.Y., additional, Caux, C., additional, Blay, J.Y., additional, Pasqual, N., additional, and Ménétrier-Caux, C., additional

Published
2012
Full Text
View/download PDF

14. ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients.

Author

Trédan, O., Ménétrier-Caux, C., Ray-Coquard, I., Garin, G., Cropet, C., Verronèse, E., Bachelot, T., Rebattu, P., Heudel, P. E., Cassier, P., Chabaud, S., Croughs, T., Dupont, P., Cadore, A. C., Clapisson, G., Delgado, A., Bardin-dit-Courageot, C., Rigal, C., N'Kodia, A., and Gilles-Afchain, L.

Subjects
*PLACEBOS, *CLINICAL trials, *CD4 antigen, *LYMPHOCYTES, *BREAST cancer patients
Abstract

Background: Lymphopenia is a predictive factor for hematological toxicity, progression and early death in advanced cancers including metastatic breast cancer (MBC). CYT107 is a recombinant interleukin 7 (IL-7) (Cytheris, now Revimmune), well tolerated and able to expand lymphocyte pool in humans. The aims of this study were to determine the optimal schedule to deliver CYT107 and to assess its effect on clinical end points. Patient and methods: This placebo-controlled, double blind, phase IIa was conducted in MBC patients with <1500/μl lymphocytes treated with capecitabine. Using a 2-by-2 factorial design, 20 patients were randomly allocated to four arms to receive (i) before chemotherapy: CYT107 or placebo; then (ii) during chemotherapy: CYT107 or placebo. The primary end point was CD4+ count changes before and during chemotherapy. Secondary end points were hematological toxicity, safety, overall response, progression-free survival (PFS) and overall survival (OS). Quantification and functional competence of circulating immune cells were also assessed. Results: When administered before chemotherapy, CYT107 induced a significant increase of CD4+ [+148.1% in CYT107 versus +9.9% in placebo groups, (Wilcoxon, P = 0.002)] and CD8+ T-cell counts, including both naïve and memory subsets. When CYT107 was administered during chemotherapy, the magnitude of CD4+ and CD8+ increase was less important. No modulation of immune cell functional competence was observed. CYT107 was well tolerated with no related ≥grade 3 adverse events except 1 fatal suspected unexpected serious adverse reaction (SUSAR) of uncertain relationship. Of the 12 cases evaluable for response, 6 of 7 patients (86%) receiving CYT107 before chemotherapy achieved a response or stabilization, whereas two of five patients (40%) receiving placebo achieved the same result. No significant difference was observed for PFS or OS. Conclusion: In lymphopenic MBC, CYT107 increases CD4+ and other T-cell subset counts without altering their function. A larger clinical trial to demonstrate its impact on clinical outcome is warranted. ClinicalTrials.gov Identifier: NCT01362107. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results